2022
mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression
Averill LA, Averill CL, Gueorguieva R, Fouda S, Sherif M, Ahn KH, Ranganathan M, D'Souza DC, Southwick SM, Sanacora G, Duman RS, Krystal JH, Abdallah CG. mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression. Journal Of Affective Disorders 2022, 303: 91-97. PMID: 35101523, DOI: 10.1016/j.jad.2022.01.104.Peer-Reviewed Original ResearchConceptsAntisuicidal effectsAntidepressant effectsSuicidal ideationKetamine-induced reductionTreatment-resistant depressionLimited treatment optionsCross-over trialMajor depressive episodeOral rapamycinPublic health crisisKetamine administrationTreatment optionsDepressive episodeParent studyOverall severityKetamineTwo weeksBeck ScaleRapamycin complex 1Mechanistic targetPatientsSignificant main effectHealth crisisRobust improvementFuture studies
2003
A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder
Sierra M, Phillips ML, Ivin G, Krystal J, David AS. A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder. Journal Of Psychopharmacology 2003, 17: 103-105. PMID: 12680746, DOI: 10.1177/0269881103017001712.Peer-Reviewed Original ResearchConceptsDepersonalization disorderEfficacy of lamotrigineWeeks of treatmentCross-over trialCross-over periodCross-over designDSM-IV depersonalization disorderSole medicationGlutamate releaseLamotriginePatientsCambridge Depersonalization ScaleDisordersTreatmentDepersonalization ScalePlaceboMedicationsHyperactivityRespondersTrialsWeeks